Vanguard Group
TPST icon

Vanguard Group’s Tempest Therapeutics TPST Stock Holding History

Vanguard Group’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$467K Hold
162,560
– – ﹤0.01% 3952
2025
Q3 		$1.67M Buy
162,560
+27,952
+21% +$243K ﹤0.01% 3631
2025
Q2 		$915K Buy
134,608
+111,694
+487% +$794K ﹤0.01% 3768
2025
Q1 		$220K Buy
22,914
+9,361
+69% +$106K ﹤0.01% 4055
2024
Q4 		$147K Hold
13,553
– – ﹤0.01% 4135
2024
Q3 		$247K Hold
13,553
– – ﹤0.01% 4101
2024
Q2 		$386K Hold
13,553
– – ﹤0.01% 4063
2024
Q1 		$689K Hold
13,553
– – ﹤0.01% 3931
2023
Q4 		$775K Sell
13,553
-2,779
-17% -$132K ﹤0.01% 3905
2023
Q3 		$64.7K Sell
16,332
-7,502
-31% -$72K ﹤0.01% 4386
2023
Q2 		$393K Buy
23,834
+4,607
+24% +$116K ﹤0.01% 4183
2023
Q1 		$580K Buy
19,227
+691
+4% +$15.2K ﹤0.01% 4082
2022
Q4 		$277K Buy
18,536
+16
+0.1% +$337 ﹤0.01% 4241
2022
Q3 		$419K Sell
18,520
-578
-3% -$17.1K ﹤0.01% 4261
2022
Q2 		$534K Sell
19,098
-63
-0.3% -$2.45K ﹤0.01% 4277
2022
Q1 		$842K Sell
19,161
-3,247
-14% -$147K ﹤0.01% 4263
2021
Q4 		$1.54M Sell
22,408
-5,220
-19% -$719K ﹤0.01% 4132
2021
Q3 		$5.2M Buy
27,628
+22,924
+487% +$4.46M ﹤0.01% 3632
2021
Q2 		$683K Buy
4,704
+2,843
+153% +$639K ﹤0.01% 4217
2021
Q1 		$436K Buy
1,861
+221
+13% +$89.3K ﹤0.01% 4154
2020
Q4 		$684K Hold
1,640
– – ﹤0.01% 3908
2020
Q3 		$521K Sell
1,640
-1,210
-42% -$410K ﹤0.01% 3804
2020
Q2 		$978K Sell
2,850
-311
-10% -$124K ﹤0.01% 3620
2020
Q1 		$3.25M Buy
3,161
+68
+2% +$99.2K ﹤0.01% 3155
2019
Q4 		$4.07M Buy
3,093
+1,045
+51% +$1.47M ﹤0.01% 3235
2019
Q3 		$2.84M Buy
2,048
+349
+21% +$563K ﹤0.01% 3332
2019
Q2 		$3.83M Buy
1,699
+651
+62% +$1.92M ﹤0.01% 3261
2019
Q1 		$3.06M Buy
1,048
+784
+297% +$1.73M ﹤0.01% 3315
2018
Q4 		$409K Sell
264
-195
-42% -$401K ﹤0.01% 3771
2018
Q3 		$980K Buy
459
+10
+2% +$24K ﹤0.01% 3728
2018
Q2 		$1.19M Sell
449
-1
-0.2% -$2.63K ﹤0.01% 3641
2018
Q1 		$1.07M Buy
450
+5
+1% +$15K ﹤0.01% 3635
2017
Q4 		$1.82M Sell
445
-78
-15% -$327K ﹤0.01% 3452
2017
Q3 		$2.17M Buy
523
+7
+1% +$29.9K ﹤0.01% 3372
2017
Q2 		$2.36M Sell
516
-49
-9% -$207K ﹤0.01% 3333
2017
Q1 		$3.09M Buy
565
+117
+26% +$545K ﹤0.01% 3236
2016
Q4 		$2M Buy
448
+34
+8% +$424K ﹤0.01% 3364
2016
Q3 		$8.68M Buy
414
+26
+7% +$470K ﹤0.01% 2752
2016
Q2 		$5.91M Buy
388
+105
+37% +$2.4M ﹤0.01% 2896
2016
Q1 		$7.86M Buy
283
+9
+3% +$190K ﹤0.01% 2738
2015
Q4 		$7.83M Buy
274
+13
+5% +$429K ﹤0.01% 2766
2015
Q3 		$6.49M Buy
261
+9
+4% +$606K ﹤0.01% 2844
2015
Q2 		$21.3M Buy
252
+31
+14% +$2.84M ﹤0.01% 2325
2015
Q1 		$22.4M Buy
221
+80
+57% +$10.7M ﹤0.01% 2277
2014
Q4 		$18.3M Buy
141
+42
+42% +$3.08M ﹤0.01% 2265
2014
Q3 		$4.83M Buy
99
+7
+8% +$245K ﹤0.01% 2841
2014
Q2 		$2.46M Buy
92
+13
+16% +$307K ﹤0.01% 3175
2014
Q1 		$2.08M Buy
79
+36
+84% +$1.02M ﹤0.01% 3207
2013
Q4 		$1.15M Buy
43
+7
+19% +$192K ﹤0.01% 3378
2013
Q3 		$1.03M Hold
36
– – ﹤0.01% 3358
2013
Q2 		$1.44M Buy
+36
New +$1.35M ﹤0.01% 3186

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group's TPST Position: Q4 2025 in Review

Vanguard Group held its Tempest Therapeutics (TPST) position steady in Q4 2025 at 162,560 shares worth $467K. The position accounts for ﹤0.01% of the portfolio, ranked #3952.

Vanguard Group first reported a position in TPST in Q2 2013 and has held it in 51 quarters since. The position peaked at $22.4M in Q1 2015. 21 funds tracked by Wall St. Rank hold TPST as of Q4 2025.

  • Vanguard Group held 162,560 shares of Tempest Therapeutics worth $467K as of Q4 2025.
  • Vanguard Group left its Tempest Therapeutics share count unchanged in Q4 2025.
  • Tempest Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3952 holding.
  • Vanguard Group first reported a position in Tempest Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Tempest Therapeutics position peaked at $22.4M in Q1 2015.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.